Deprenyl in Parkinson's disease.

Abstract

In a double-blind crossover trial, (-)-deprenyl, a fast-acting selective monoamine-oxidase-B inhibitor without a "cheese effect", was given to 41 patients with idiopathic Parkinson's disease who were receiving maximum tolerated doses of levodopa either alone or combined with carbidopa ("Sinemet"). In a dose of 10 mg, daily or on alternate days, (-)-deprenyl prolonged the therapeutic effect of levodopa and was effective in mild "on-off" disabilities with end-of-dose akinesia; the majority of patients with nocturnal and early-morning akinesia also improved. No statistically significant improvement occurred in diurnal akinesia, and there was no improvement in patients with severe on-off disabilities with freezing and rapid oscillations ("yo-yo" effect). Levodopa-induced dyskinesias were aggravated in 14 patients. In 5 previously untreated patients, (-)-deprenyl alone gave no benefit, but when it was used with levodopa and carbidopa a mean dosage reduction of 200 mg levodopa daily was possible. Depression, present in 15 patients, was unchanged. (-)-Deprenyl in combination with smaller total daily doses of levodopa and a peripheral decarboxylase inhibitor may prove useful in reducing the frequency and severity of some types of on-off effect with overall benefit comparable to that obtained with larger doses of levodopa.

Statistics

0100200'78'81'85'89'93'97'01'05'09'13'17
Citations per Year

1,123 Citations

Semantic Scholar estimates that this publication has 1,123 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Lees1977DeprenylIP, title={Deprenyl in Parkinson's disease.}, author={A. J. Lees and Kenneth M Shaw and Ladislav J. Kohout and G. M. Stern and John D. Elsworth and Maya Sandler and Moussa B. H. Youdim}, journal={Lancet}, year={1977}, volume={2 8042}, pages={791-5} }